ANS03
Phase 1Small molecule
ANS03 is one of 22 small molecule programs targeting Locally Advanced or Metastatic Solid Tumors. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Locally Advanced or Metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 2
Keytruda
Merck & Co.Phase 2
Vitrakvi
BayerPhase 2
Stivarga
BayerPhase 2
Afinitor
NovartisPhase 2
OPDUALAG
Bristol-Myers SquibbPhase 2
Cabometyx
Bristol-Myers SquibbPhase 1
Budigalimab
AbbViePhase 1
Livmoniplimab
AbbViePhase 1
N-803
IImmunityBio, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ANS03. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAvistone Biotechnology Co., Ltd.